| Name | Title | Contact Details |
|---|---|---|
Justin Scheidegger |
Director, IT Operations, Infrastructure and Security | Profile |
Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.
International Drug Development Institute is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Madeira Therapeutics is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Timken Radiology is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.